The Promise of Combining Inhibition of PI3K and PARP as Cancer Therapy

Abstract excerpt

Abstract Analyses of in vitro and patient-derived in vivo models of breast cancer reveal that a combination of inhibitors of the enzymes PARP and phosphoinositide 3-kinase (PI3K) is a potentially effective treatment regimen for breast cancer tumors with elevated activity of the PI3K pathway. Cancer Discov; 2(11); 982–4. ©2012 AACR. Commentary on Ibrahim et al., p. 1036. Commentary on Juvekar et al., p. 1048.

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to BRCA gene mutations in cancer
• Share to DNA Repair Mechanisms
• Share to PARP inhibition in cancer therapy